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Abstract 
Objective: Oral cancers are slow developing tumors that affect thousands of individuals in the US 
annually. Evidence has shown that these cancers can create microenvironments to enhance their 
progression, survival and metastasis characteristics. Cancer cells will compete for extracellular 
nutrients with normal tissue cells, which can cause irregularities in immune regulation of 
progressive cancers. Recent evidence in other types of cancers have suggested that tumor cells may 
actually upregulate the consumption of extracellular L-tryptophan and increase the export of 
cytosolic kynurenine byproduct. These kynurenines have been linked to suppression of local 
immune response of T-cells. The primary goal of this study was to evaluate oral cancer cell lines for 
tryptophan dioxygenase (TDO) and Indolamine 2,3-dioxygenase (IDO) expression and elucidate 
whether or not other flavonoids inhibit enzyme expression and cancer growth. Methods: Oral 
cancer cell lines SCC25, SCC15, and CAL27 were screened for enzyme expression using mRNA 
specific primers and RT-PCR.  The three cell lines were then subjected to proanthocyanidin (PAC) 
administration to determine potential growth and enzyme inhibition. Results: This study found that 
IDO and TDO are expressed in the SCC25, SCC15, and CAL27 oral cancer cell lines and enzyme 
expression is correlated with tumor growth. Additionally, it was observed that IDO and TDO 
expression, along with tumor growth, can be inhibited by flavonoid administration. Conclusions: 
With no real treatment advances in many years and survival rates remaining relatively unchanged, 
these results provide further knowledge in the understanding of oral cancer mechanisms and 
function that may lead to future treatment modalities. Our demonstration of enzyme down 
regulation and growth inhibition induced by flavonoids may also contribute to further research in 
future novel treatments.  
© 2012 GESDAV 
 
INTRODUCTION 
Oral cancers develop very slow over many years or 
decades and have  recently been found to affect nearly 
30,000 people annually in the US [1,2]. Oral health 
researchers and oncologists generally concur that most 
oral cancers are initiated due to the long-term use of 
tobacco and alcohol [3,4], although the mechanisms of 
oral carcinogenesis entail distinct and variable changes 
in the molecular systems, architecture, and genetics of 
each individual tumor [5,6]. Recent evidence suggests 
that aggressive tumors, including those of the oral 
cavity, create microenvironments with many common 
features that promote tumor progression, survival, 
angiogenesis, and metastasis [7]. 
One common cellular feature of oral cancers is 
accelerated growth and proliferation, which is 
dependent upon the uptake and metabolism of various 
micronutrients used in biosynthesis and energy 
generation [8,9]. For example, research has 
demonstrated that folic acid, which is crucial for DNA 
synthesis and repair, as well as specific metabolic 
processes, including DNA methylation via S-
adenosylmethionine, is closely regulated in most 
tissues but may be dysregulated during oral 
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carcinogenesis [10-14]. More recent evidence now 
suggests that L-Tryptophan, an amino acid essential for 
growth and a variety of other cellular processes, 
including protein synthesis and both NADH / NADPH 
formation [15], may be preferentially imported and 
metabolized in many human cancers [16], such as those 
of the oral cavity [15,17]. 
Uptake of L-tryptophan into human cells may involve a 
variety of L-amino acid transporter (LAT)  proteins, 
but mainly LAT1 counter-transport proteins that import 
extracellular  L-tryptophan in exchange for the 
cytosolic by-product kynurenine following  tryptophan 
catabolism within the cell by tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase 
enzymes (IDO) [18,19,20].   This exchange system 
functions not only to accelerate carcinogenesis by 
increasing L-tryptophan uptake from the local 
microenvironment, thus reducing availability to other 
cells, but also by up-regulating the export and 
extracellular concentration of kynurenines, which may 
play a significant role in suppressing the local adaptive 
immune response of T-cells [21-26].  
OBJECTIVE 
A few preliminary studies have observed the 
tryptophan influx/kynurenine efflux cycle in one or 
more oral cancer cell lines [15,17]. Several studies have 
demonstrated increased anti-tumor immunosuppression 
and tumor growth inhibition by down-regulation or 
interference with IDO [27-29]. However, only one 
study to date has successfully demonstrated IDO 
inhibition, transcriptional down-regulation, and growth 
inhibition in oral cancer cells (using the flavonoid 
epigallocatechin-3-gallate), as well as the elucidation of 
associated intracellular signaling pathways affected 
[17]. Therefore, the purpose of this study was to 
evaluate additional oral cancer cell lines, not previously 
examined, for IDO and TDO expression and to explore 
the inhibitory potential of other flavonoids on IDO and 
TDO expression.  Based upon previous evidence, the 
working hypothesis was that cellular phenotypes that 
exhibit accelerated growth and proliferation may be 
correlated with expression of these enzymes. 
Furthermore, flavonoids may not only inhibit oral 
cancer growth but also IDO and TDO expression. 
These findings may be useful as they explore the 
potential effects of flavonoids as prevention and 
secondary treatment options for patients with oral 
cancer.  
METHODS 
Cell lines 
The human oral scquamous cell carcinoma (OSCC) cell 
lines used in this study, CAL27 (CRL-2095), SCC15 
(CRL-1623), and SCC25 (CRL-1628) were obtained 
from American Type Culture Collection (ATCC: 
Manassas, VA). CAL27 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 
mM L-glutamine, adjusted to contain 3.7 g/L sodium 
bicarbonate and 4.5 g/L glucose from Hyclone (Logan, 
UT). SCC15 and SCC25 cells were maintained in a 1:1 
mixture of DMEM and Ham’s F12 medium with 2.5 
mM L-glutamine, modified to contain 15 mM HEPES, 
0.5 mM sodium pyruvate, and 1.2 g/L sodium 
bicarbonate (ATCC), supplemented with 400 ng/ml 
hydrocortisone from Sigma-Aldrich (St. Louis, MO). 
The control oral cell line HGF-1 (CRL-2014) was 
maintained in DMEM with 4 mM L-glutamine, 
adjusted to contain 3.7 g/L sodium bicarbonate and 4.5 
g/L glucose, from Hyclone (Logan, UT). Media for all 
cell lines were supplemented with 10% fetal bovine 
serum (FBS), and with 1% Penicillin (10,000 
units/mL)-Streptomycin (10,000 μg/mL) solution 
(HyClone). Cell cultures were maintained in 75 cm2 
Becton, Dickinson (BD) Falcon tissue-culture treated 
flasks (Bedford, MA) at 37°C and 5% CO2 in 
humidified chambers. 
RNA isolation, concentration, and yield  
RNA was isolated from 1.5 x 107 cells of each of the 
experimental cell lines, using ABgene Total RNA 
Isolation Reagent (Epsom, Surrey, UK) in accordance 
with the procedure recommended by the manufacturer.  
RNA purity and concentration and purity were 
calculated using UV spectroscopy.  The absorbance of 
diluted RNA samples (10 µL of RNA sample in 490 µL 
nuclease-free water, pH 7.0) was measured at 260 and 
280 nm.  RNA purity was determined by calculating 
the ratio of A260:A280, and comparing it to the 
expected ratio which should be > 1.80. Concentration 
of RNA samples was determined by the A260 reading 
of 1 = 40 µg/mL RNA, based on an extinction 
coefficient calculated for RNA in nuclease-free water.  
Concentration was then calculated as 40 x A260 
absorbance measure x dilution factor (50).  Total yield 
was determined by concentration x sample volume in 
mL.   
Example: 
RNA standard  
A260 = 0.75  
Concentration = 40 x 0.75 x 50 = 1,500 µg/mL  
Yield = 1,500 µg/mL x 1.0 mL = 1,500 µg or 1.5 mg 
RNA 
Reverse-transcription polymerase chain reaction (RT-
PCR)  
To quantify the expression of  specific mRNA, RT-
PCR was performed on total RNA using the ABgene 
Reverse-iT One-Step RT-PCR Kit (ReadyMix Version) 
and a Mastercycler gradient thermocycler (Eppendorf: 
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Hamburg, Germany) using the following primers for 
IDO [30], IDO2 [31], TDO [32], c-myc [33] , ornithine 
decarboxylase ODC [34] , caspase-2 [35], caspase-8 
[36], and GAPDH [37], synthesized by SeqWright 
(Houston, TX): 
IDO-forward  
5′-TGTCCGTAAGGTCTTGCCAGG-3′;  
IDO-reverse   
5′-CGAAATGAGAACAAAACGTCC-3′;  
IDO2-forward   
5′-GACTACAAGAATGGCACACG-3’; 
IDO2-reverse  
5′ AATGTGCTCTTGTTGGGTTAC-3’; 
TDO-forward  
5’-GGG CATATG AAAAAACTCCCCGTAGAAGG-
3’; 
TDO-reverse  
5’-GGGGATCCTTAATCTGATTCATCACTGCTG 
AAGTAGG-3’; 
c-myc forward primer, 
5’-TCCAGCTTGTACCTGCAGGATCTGA-3’; 
c-myc reverse primer,  
5’-CCTCCAGCAGAAGGTGATCCAGACT-3’; 
ODC forward primer,  
5’-AATCAACCCAGCGTTGGACAA-3’; 
ODC reverse primer,  
5’-ACATCACATAGTAGATCGTCG-3’; 
caspase-2 forward primer,  
5’-TGGCATATAGGTTGCAGTCTCGG-3’; 
caspase-2 reverse primer,  
5’-TGTTCTGTAGGCTTGGGCAGTTG-3’; 
caspase-8 forward primer,  
5’-GATATTGGGGAACAACTGGAC-3’; 
caspase-8 reverse primer,  
5’-CATGTCATCATCCAGTTTGCA-3’; 
GAPDH forward primer,  
5’-ATCTTCCAGGAGCGAGATCC-3’; 
GAPDH reverse primer,  
5’-ACCACTGACACGTTGGCAGT-3’; 
One µg of template (total) RNA was used for each 
reaction.  The reverse transcription step ran for 30 
minutes at 47°C, followed by denaturation for 2 
minutes at 94°C.  Thirty-five amplification cycles were 
run, consisting of 20 second denaturation at 94°C, 30 
seconds of annealing at 58°C, and 6.5 minutes of 
extension at 72°C.  Final extension was run for 5 
minutes at 72°C.  Reaction products were separated by 
gel electrophoresis using Reliant 4% NuSieve® 3:1 
Plus Agarose gels (Lonza: Rockland, ME).  Bands were 
visualized by UV illumination of ethidium-bromide-
stained gels and captured using a Kodak Gel Logic 100 
Imaging System and 1D Image Analysis Software 
(Eastman Kodak: Rochester, NY).  Quantitation of RT-
PCR band densitometry and relative mRNA expression 
levels were performed using Adobe Photoshop (San 
Jose, CA) imaging software, Image Analysis tools.   
Proliferation (growth) assays 
Proliferation assays were performed in the appropriate 
complete media in Corning Costar 96-well assay plates 
(Corning, NY) at a concentration of 1.2 x 104 cells per 
well, and proliferation was measured over three days. 
Cultured cells were fixed at three time points, after 24 
hrs (day 1 or d1), after 48 hrs (day 2 or d2), and after 
72 hrs (day 3 or d3) using 50 μL of 10% buffered 
formalin, and were stained with crystal violet 1% 
aqueous solution (Fisher Scientific: Fair Lawn, NJ). 
The relative absorbance was measured at 630 nm using 
a Bio-Tek ELx808 microplate reader (Winooski, VT). 
Data were analyzed and graphed using Microsoft Excel 
(Redmond, WA). Three separate, independent 
replications of each experiment were performed. 
Relative-fold increase (RFI)  
Trypsinizing and plating cells may have proliferation-
stimulating effects within laboratory cell culture-based 
assays, which have been observed between d0 and d1 
in previously published work involving this specific 
method of proliferation assay in these cell lines [38-
43]. To reduce the overall impact of these effects, the 
relative change in proliferation, measured as the change 
or relative-fold increase (RFI) in absorbance between 
d3 and d1, was calculated to more accurately assess the 
changes induced by these experimental treatments. 
Viability 
Prior to plating cells for proliferation assays, aliquots of 
trypsinized cells were stained using Trypan Blue 
(Sigma: St. Louis, MO), and live cells were enumerated 
by counting the number of Trypan-blue negative cells 
using a VWR Scientific Counting Chamber (Plainfield, 
NJ) and a Zeiss Axiovert 40 inverted microscope 
(Gottingen, Germany).  At each time point (day 1-3), 
several wells were processed using the Trypan stain, 
and live (viable) cells were enumerated, and the overall 
percentage calculated, using this procedure. 
Materials 
Proanthocyanidin (PAC) (Lot #3717HF7361), a dietary 
supplement intended to provide a concentrated source 
of commonly available fruit-derived flavonoids, was 
obtained from GNC Preventive Nutrition® (Pittsburgh, 
PA).  This commercial source of PAC was extracted 
from U.S. grown wine grapes, Vitus vinifera.  Such 
commercial sources of grape seed PAC extract are 
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demonstrated to contain 95% PAC and contain 
approximately 80-90% oligomeric PACs, including 
dimers, trimers, tetramers, and a small amount of other 
monomers [41,42,44]. The total concentrations of PAC 
used were between 10 and 100 μg/mL, added to the 
complete media prior to the start of each experimental 
assay and cell plating.  The growth inhibitory 
maximum (GIMAX) previously determined for these 
cell lines was confirmed at 50 µg/mL [41,42]. Three 
independent replications of each experiment for each 
cell line (CAL27, SCC25, SCC15) were performed, 
each consisting of eight wells per experimental 
concentration. 
Statistics 
Comparisons of the effects of treatments were made 
using two-tailed t tests with α ≤ 0.05. All samples were 
analyzed using two-tailed t tests as departure from 
normality can make more of a difference in a one-tailed 
than in a two-tailed t test [45]. As long as the sample 
size is even moderate (>20) for each group, quite 
severe departures from normality make little practical 
difference in the conclusions reached from these 
analyses. 
RNA was extracted from the OSCC cell lines CAL27, 
SCC25, and SCC15 to analyze IDO and TDO mRNA 
expression using RT-PCR (Figure 1).  This analysis 
revealed expression of IDO and TDO mRNA in all 
three cell lines, although the levels in each of the cell 
lines varied significantly relative to their GAPDH 
levels (Fig 1A).  In addition, CAL27 and SCC25 cells 
expressed comparatively greater levels of IDO mRNA 
than did SCC15 cells.   
RESULTS 
 
Figure 1. 
To determine if proliferation or growth rates, measured 
by relative-fold increase (RFI) in growth after three 
days (3d), may be associated with these observations, 
an analysis was performed revealing IDO mRNA 
expression strongly correlated with RFI in CAL27, 
SCC25, and SCC15 cells, R=0.90, 0.91, and 0.76, 
respectively (Fig 1B). More specifically, the cell lines 
with the highest RFI (CAL27 and SCC25) were 
observed to express higher levels of IDO than SCC15 
cells.  
 
 
 
Figure 2. 
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To determine if these cell lines down-regulate IDO 
expression and are growth-inhibited by flavonoids, as 
previously observed with OSCC cell lines and 
epigallocatechin [17], a more diverse group of 
flavonoids (PACs) were administered at the GIMAX of 
50 µg/mL (Figure 2).  These experiments demonstrated 
that PACs were sufficient to significantly inhibit 
proliferation in a dose-dependent manner up to the 
growth inhibitory maximum (GIMAX) of 50 µg/mL (-
36 to 58%, p<0.05), confirming previous observations 
in CAL27 and SCC25 cells [40-42], but also 
demonstrating these effects in SCC15 cells (Fig 2A). 
To determine if the growth inhibition induced by PAC 
administration also influenced IDO, RT-PCR was 
utilized to reveal a down-regulation in IDO mRNA in 
all cell lines (Fig. 2B). This decrease also corresponded 
with a down-regulation in the cell-cycle promoter c-
myc, confirming previous observations [40,41]. 
To more accurately assess these effects and the possible 
mechanisms responsible, other key cell-cycle, survival 
and apoptosis-specific regulatory genes, including 
ODC, caspase-2, caspase-8, as well as TDO were 
assessed (Table 1).  These analyses demonstrated that 
PAC administration is associated with down-regulation 
of both IDO and TDO mRNA between -0.3 and -0.95-
fold. These analyses also confirmed the previously 
observed down-regulation of key growth-promoting 
regulators c-myc and ODC, as well as the up-regulation 
of apoptosis initiators and effectors, caspase-2 and 
caspase-8 [40]. Furthermore, these observations 
correlated with decreased cell viability (ranging from -
0.42 and 0.82-fold) and growth (between 0.36 and -
0.58). 
 
Table 1. PAC induced effects on mRNA expression, growth 
and viability in oral cancer cells. 
 CAL27 SCC25 SCC15 
IDO -0.85 -0.95 -0.30 
TDO -0.50 -0.55 -0.30 
c-myc -0.90 -0.65 -0.45 
ODC -0.45 -0.60 -0.35 
Caspase-2 +0.70 +1.10 +0.65 
Caspase-8 +0.80 +0.60 +0.55 
RFI -0.58 -0.56 -0.36 
Viability -0.71 -0.83 -0.42 
 
These data provide evidence that administration of 
PACs may, directly or indirectly, down-regulate 
mRNA expression of both IDO and TDO in oral cancer 
cell lines (Figure 3).  In addition, these data confirm 
previous observations suggesting that other key oral 
cancer cell-cycle signaling molecules, such as ODC 
and c-myc may also be down-regulated by PAC 
administration [40-42] – although these data may be the 
first to demonstrate that this process may occur in 
tandem.  When combined with other previous reports 
of flavonoid-induced signaling interactions involving 
STAT [17] and FAK [46], a more comprehensive 
system involving the upstream and downstream effects 
of flavonoid-induced growth inhibition of oral cancer 
growth emerges. 
 
Figure 3. 
DISCUSSION 
The purpose of this study was to investigate whether 
previously unscreened oral cancer cell lines, expressed 
IDO and TDO; and additionally to explore whether this 
expression is correlated with any specific cellular 
phenotype. To test this hypothesis, a comprehensive 
series of integrated in vitro assays were performed that 
clearly demonstrate SCC25 and SCC15 cells expressed 
both IDO and TDO mRNA, as well as confirming this 
expression in CAL27 oral cancer cells.  In addition, the 
differential expression of IDO, exhibited strong and 
positive correlations with cellular growth and 
proliferation rates. These experiments demonstrated 
that PACs were sufficient to significantly inhibit 
proliferation in a dose-dependent manner up to the 
growth inhibitory maximum. Finally, although these 
data confirm the growth-inhibitory properties of PACs 
on oral cancers [40-42,47,48], these data may be the 
first to demonstrate the potential for PACs and other 
fruit-derived flavonoids to inhibit IDO (and TDO) 
expression, similar to the effects previously observed 
with epigallocatechin-3-gallate [17], as well as an 
analysis of corresponding changes to key intracellular 
signaling molecules involved in cell cycle progression 
and the initiation of apoptosis. 
Although several previous studies have evaluated the 
potential pro-growth and immune-evasion mechanisms 
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of IDO and TDO expression in other cancers [18-20], 
to date, only a few select studies have examined these 
processes in oral cancers [15,17]. The current study, 
therefore, provides novel data and further elucidation 
towards the understanding of how oral cancers function 
not only to increase survival and viability, but also to 
simultaneously down-regulate and evade local 
immunomodulatory responses [21,22,25,26]. In 
addition, these data provide novel evidence that IDO 
mRNA expression, but not TDO levels, may be 
correlated with oral cancer growth rates – a finding that 
may help to contextualize the understanding of the 
active, but differential, regulation of these enzymes in 
other oral cancer cell lines and tumors. In addition, this 
study provides novel data to suggest that PACs, and 
other flavonoids, may be sufficient to inhibit growth 
and down-regulate IDO expression in these cells. 
A limitation of this study, similar to other preclinical 
studies, involves the use of oral cancer cell lines.  
These cells may harbor karyotypic alternations or other 
dissimilar genetic mutations that may potentially 
influence the experimental outcomes of this study.  For 
example, CAL27 cells contain a nonsense mutation in 
the SMAD4 gene, which may influence the 
transforming growth factor (TGF) signaling pathway 
and cell growth potential [49]. In addition, SCC25 cells 
are known to harbor a deletion in the cell cycle 
promoter cdk1, resulting in a deletion of a critical 
transcriptional regulation sequence [50]. SCC15 cells 
however, harbor a single nucleotide polymorphism 
(SNP) that alters the expression of the tumor 
suppressor, S100A2 [51]. However, although oral 
cancers may harbor many genetic mutations and 
deletions, many lines of evidence now suggest that 
dysregulation and reduced expression of many tumor 
suppressors in oral cancers may, in fact, be the result of 
hypermethylation events rather than fixed genetic 
differences [52-54]. 
CONCLUSIONS 
Although many studies have found that oral 
carcinogenesis may be strongly influenced by the 
ability of tumor cells to alter the local 
microenvironment, new evidence suggests that the 
ability to alter micronutrient uptake (L-tryptophan), 
while down-regulating adaptive immune responses to 
tumor growth may be critical to tumor growth and 
metastasis.  This study may be the first to provide new 
evidence that IDO and TDO expression are found in 
SCC25 and SCC15 cells, as well as CAL27 cells, and 
to demonstrate that PAC administration is not only 
sufficient to inhibit oral cancer growth, but may also be 
associated with IDO and TDO mRNA down-
regulation.   
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